Phase 3 Studies of Azilsartan Medoxomil Plus Chlorthalidone for Hypertension
Takeda Global Research & Development Center, Inc. announced results from three Phase 3 studies of azilsartan medoxomil (Edarbi; Takeda Pharmaceuticals North America) plus chlorthalidone for the treatment of hypertension. In two of the studies, azilsartan medoxomil combined in a fixed-dose with chlorthalidone lowered clinic systolic blood pressure (SBP) significantly more than the fixed-dose combinations of olmesartan medoxomil plus hydrochlorothiazide (HCTZ). The other study demonstrated that six fixed-dose combinations of azilsartan medoxomil plus chlorthalidone lowered mean trough (22–24 hours) SBP by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) significantly more than either azilsartan medoxomil or chlorthalidone alone.
Azilsartan medoxomil plus chlorthalidone is an investigational fixed-dose combination for the treatment of hypertension. The fixed-dose combination of azilsartan medoxomil plus chlorthalidone contains two medications: azilsartan medoxomil (Edarbi; Takeda Pharmaceuticals North America), an angiotensin II receptor blocker, and chlorthalidone, a long-acting diuretic used in the treatment of hypertension.
For more information call (224) 554-6500 or visit www.tpna.com.